

CRITERIA FOR INCLUSION/EXCLUSION OF STUDIES IN THE REVIEW

Domain	Inclusion	Exclusion
Population .....	<ul style="list-style-type: none"> <li>Publications that address quality of care indicators, criteria, or benchmarks. We will accept the authors' definition of quality of care. Quality indicators may include care processes-related measures (e.g., follow-up post discharge, continuity of care, medication errors), health services utilization measures (e.g., hospital readmission, emergency department visit), care satisfaction (e.g., patient satisfaction, care needs met, trust in care provider), or health outcomes (e.g., mortality, physical functional status, mental functioning, quality of life) used as quality indicators. Publications that do not address quality of care in detail but include quality of care and health equity in a framework will also be eligible. Care disparities may either address differences in provided health services, focus on care services or health outcomes of priority populations.</li> </ul>	<ul style="list-style-type: none"> <li>Publications not addressing quality of care and publications not mentioning quality of care nor health equity as a central feature of a framework.</li> </ul>
Concept .....	<ul style="list-style-type: none"> <li>Publications that include a figure or detailed description of a framework of quality of care or care disparities; frameworks may use the format of a logic model, analytic framework, conceptual model, or other conceptualizations of quality of care.</li> </ul>	<ul style="list-style-type: none"> <li>Publications citing existing frameworks without further conceptual contribution to the framework and publications describing only the need of quality of care measures.</li> </ul>
Context .....	<ul style="list-style-type: none"> <li>Healthcare, specifically healthcare delivery organizations .....</li> </ul>	<ul style="list-style-type: none"> <li>Studies in contexts outside of healthcare or not specific to healthcare.</li> </ul>
Other limiters .....	<ul style="list-style-type: none"> <li>Reports published in English-language, journal manuscripts, trial records, and gray literature in the public domain from the outlined sources.</li> </ul>	<ul style="list-style-type: none"> <li>Data reported in abbreviated format (e.g., conference abstracts) will be excluded; studies not published in English</li> <li>Systematic reviews will be retained for reference mining.</li> </ul>

Dated: October 12, 2023.  
**Marquita Cullom**,  
 Associate Director.  
 [FR Doc. 2023-22915 Filed 10-17-23; 8:45 am]  
**BILLING CODE 4160-90-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 5 U.S.C. Section 1009(d), notice is hereby given of the following meeting.  
 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.  
*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE24-013, Research Grants to Identify

Effective Community-Based Strategies for Overdose Prevention (R01).  
*Date:* March 12-13, 2024.  
*Time:* 8:30 a.m.-5 p.m., EDT.  
*Place:* Web Conference.  
*Agenda:* To review and evaluate grant applications.  
*For Further Information Contact:* Aisha L. Wilkes, M.P.H., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341, Telephone: (404)639-6473; Email: [AWilkes@cdc.gov](mailto:AWilkes@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh**,  
 Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.  
 [FR Doc. 2023-23006 Filed 10-17-23; 8:45 am]  
**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.  
 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.  
*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE24-029, Grants to Support New Investigators in Conducting Research Related to Preventing Interpersonal Violence Impacting Children and Youth.  
*Date:* March 19, 2024.  
*Time:* 8:30 a.m.-5 p.m., EDT.  
*Place:* Web Conference.  
*Agenda:* To review and evaluate grant applications.